ArticleScientific reports2026
Enhanced glucose forecasting using recurrent neural network and advanced feature engineering.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to develop an artificial intelligence (AI)-driven pipeline for forecasting blood glucose levels to mitigate risks associated with hypoglycemia and hyperglycemia. The main research question focuses on the effectiveness of hybrid data preprocessing and feature engineering in enhancing glucose level predictions. The proposed approach employs a hybrid methodology for handling missing data and advanced feature engineering techniques. A recurrent neural network (RNN) model is developed to forecast glucose levels with a lead time of 30 minutes. The model is evaluated using metrics such as root mean square error (RMSE) and mean absolute error (MAE). Experimental results indicate that the proposed pipeline achieves an average RMSE of 19.64 ± 0.11 and an MAE of 13.54 ± 0.11 across all patients. The results demonstrate improved forecasting accuracy, enabling early detection of critical glucose fluctuations. The integration of hybrid preprocessing and RNN modeling effectively predicts glucose levels, providing valuable insights for diabetes management. This approach supports better prevention of glucose emergencies, ultimately enhancing the quality of life for individuals with diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.